📣 VC round data is live. Check it out!
- Public Comps
- Indegene
Indegene Valuation Multiples
Discover Indegene's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like iFLYHealth, Schrödinger, CareDx, JMDC and more.
Indegene Overview
About Indegene
Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical device companies. It assists them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations for life sciences companies. The company's segments include Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment. The company has a presence in India, Europe, and North America, with the majority of revenue coming from North America.
Founded
1998
HQ

Employees
5.0K
Website
Financials (LTM)
EV
$1B
Valuation Multiples
Start free trialIndegene Financials
Indegene reported last 12-month revenue of $384M and EBITDA of $68M.
In the same LTM period, Indegene generated $131M in gross profit, $68M in EBITDA, and $45M in net income.
Revenue (LTM)
Indegene P&L
In the most recent fiscal year, Indegene reported revenue of $370M and EBITDA of $71M.
Indegene is profitable as of last fiscal year, with EBITDA margin of 19% and net margin of 12%.
Financial data powered by Morningstar, Inc.
Indegene Stock Performance
Indegene has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Indegene's stock price is $5.37.
Indegene share price decreased by 2.3% in the last 30 days, and by 13.7% in the last year.
Indegene has an EPS (earnings per share) of $0.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -2.3% | -2.3% | 15.3% | -13.7% | $0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIndegene Valuation Multiples
Indegene trades at 3.0x EV/Revenue multiple, and 16.8x EV/EBITDA.
EV / Revenue (LTM)
Indegene Financial Valuation Multiples
As of June 2, 2026, Indegene has market cap of $1B and EV of $1B.
Indegene has a P/E ratio of 28.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Indegene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Indegene Margins & Growth Rates
Indegene grew revenue by 23% and EBITDA by 16% in the last fiscal year.
In the most recent fiscal year, Indegene reported EBITDA margin of 19% and net margin of 12%.
Indegene Margins
Indegene Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Indegene Operational KPIs
Indegene's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Indegene's Rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Indegene's Rule of X is 75% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Indegene Competitors
Indegene competitors include iFLYHealth, Schrödinger, CareDx, JMDC, Vitec Software, Omada Health, Sphere, GeneDx, U.S. Physical Therapy and Certara.
Most Indegene public comparables operate across Healthcare Software, Health Data & Analytics, B2B SaaS, Vertical SaaS and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 9.5x | 8.5x | (245.4x) | (237.7x) | |||
| 3.5x | 3.6x | (6.4x) | (6.4x) | |||
| 2.7x | 2.5x | 32.0x | 25.3x | |||
| 5.0x | 3.9x | 18.1x | 15.1x | |||
| 3.5x | 3.5x | 8.9x | 9.3x | |||
| 3.5x | 3.1x | 138.8x | 80.5x | |||
| 19.7x | - | 206.0x | - | |||
| 3.6x | 3.4x | 38.1x | 61.2x | |||
This data is available for Pro users. Sign up to see all Indegene competitors and their valuation data. Start Free Trial | ||||||
Indegene VC Funding History
Before going public, Indegene raised $769M in total equity funding, across 4 rounds.
Last private valuation of Indegene was $700M, after raising $200M in February 2021 from Brighton Park Capital and Carlyle Group.
Indegene Funding Rounds
Acquisitions by Indegene
Indegene has acquired 10 companies to date.
Last acquisition by Indegene was on February 18th 2026. Indegene acquired CAKE Kommunikation for $10M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Indegene
| Description | CAKE Kommunikation is a healthcare marketing agency providing pharmaceutical communications, brand strategy, and medical content for the industry. | BioPharm Communications is a Blue Bell-headquartered agency delivering multichannel campaigns for pharma clients targeting US physicians. It uses Salesforce Marketing Cloud and proprietary HCP data for email, video, and print distribution of clinical trial results. Founded in 2000, the firm serves companies like AstraZeneca and GSK with adherence programs. | M J L is a London-based independent advertising agency focused on biological life sciences and veterinary farming sectors. It delivers integrated campaigns encompassing strategy, creative development, digital marketing, and media planning for pharmaceutical companies, biotech firms, and agribusiness clients. Notable projects include promotional materials for animal health products and medical device launches, with expertise in regulatory-compliant content for EU markets. The agency maintains a portfolio serving clients like veterinary pharmaceutical leaders and crop protection specialists across the UK and Europe. | Trilogy Writing & Consulting is a contract research organization offering regulatory writing services for clinical trials and drug development. Located in Princeton, New Jersey, the firm produces clinical study reports, investigator brochures, protocols, and CTD dossiers compliant with FDA, EMA, and ICH guidelines. Serving biotech, pharma, and medical device clients worldwide, Trilogy supports Phase I-IV studies and has authored documents for over 300 submissions. With a team of PhD-level writers, the company delivers plain-language summaries and health authority responses, accelerating approval timelines. | |
| HQ Country | |||||
| HQ City | - | Philadelphia, PA | Stevenage | Frankfurt | |
| Deal Date | 18 Feb 2026 | 1 Oct 2025 | 26 Mar 2025 | 27 Mar 2024 | |
| Valuation | $10M | $104M | $4M | $400K | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Indegene acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Indegene
| When was Indegene founded? | Indegene was founded in 1998. |
| Where is Indegene headquartered? | Indegene is headquartered in India. |
| How many employees does Indegene have? | As of today, Indegene has over 5K employees. |
| Who is the CEO of Indegene? | Indegene's CEO is Manish Gupta. |
| Is Indegene publicly listed? | Yes, Indegene is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Indegene? | Indegene trades under INDGN ticker. |
| When did Indegene go public? | Indegene went public in 2024. |
| Who are competitors of Indegene? | Indegene main competitors include iFLYHealth, Schrödinger, CareDx, JMDC, Vitec Software, Omada Health, Sphere, GeneDx, U.S. Physical Therapy, Certara. |
| What is the current market cap of Indegene? | Indegene's current market cap is $1B. |
| What is the current revenue of Indegene? | Indegene's last 12 months revenue is $384M. |
| What is the current revenue growth of Indegene? | Indegene revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Indegene? | Current revenue multiple of Indegene is 3.0x. |
| What is the current EBITDA of Indegene? | Indegene's last 12 months EBITDA is $68M. |
| What is Indegene's EBITDA margin? | Indegene's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Indegene? | Current EBITDA multiple of Indegene is 16.8x. |
| What is the current FCF of Indegene? | Indegene's last 12 months FCF is ($8M). |
| What is Indegene's FCF margin? | Indegene's last 12 months FCF margin is (2%). |
| What is the current EV/FCF multiple of Indegene? | Current FCF multiple of Indegene is (139.3x). |
| How many companies Indegene has acquired to date? | As of June 2026, Indegene has acquired 10 companies. |
| What was the largest acquisition by Indegene? | $104M acquisition of BioPharm Communications on 1st October 2025 was the largest M&A Indegene has done to date. |
| What companies Indegene acquired? | Indegene acquired BioPharm Communications, Encima Group, Medical Marketing Economics, DT Associates, CAKE Kommunikation, SKURA, M J L, Trilogy Writing & Consulting, CultHealth, and Wincere. |
| In how many companies Indegene has invested to date? | Indegene hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Indegene
Lists including Indegene
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.



